Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Acquisitions & Divestments (2017 - 2025)

Historic Change in Acquisitions & Divestments for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $107.1 million.

  • Denali Therapeutics' Change in Acquisitions & Divestments fell 4591.87% to $107.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $782.0 million, marking a year-over-year decrease of 3961.59%. This contributed to the annual value of $1.2 billion for FY2024, which is 4426.06% down from last year.
  • Latest data reveals that Denali Therapeutics reported Change in Acquisitions & Divestments of $107.1 million as of Q3 2025, which was down 4591.87% from $162.2 million recorded in Q2 2025.
  • Denali Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $601.1 million for Q3 2023, and its period low was $107.1 million during Q3 2025.
  • In the last 5 years, Denali Therapeutics' Change in Acquisitions & Divestments had a median value of $293.1 million in 2021 and averaged $319.2 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first surged by 31646.26% in 2023, then tumbled by 6706.14% in 2024.
  • Over the past 5 years, Denali Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $193.8 million in 2021, then surged by 87.87% to $364.0 million in 2022, then skyrocketed by 34.34% to $489.0 million in 2023, then fell by 28.22% to $351.0 million in 2024, then tumbled by 69.49% to $107.1 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $107.1 million for Q3 2025, versus $162.2 million for Q2 2025 and $161.8 million for Q1 2025.